Expression and Clinical Significance of CD30 and CD56 in Lymphoblastic Lymphoma: A Retrospective Analysis on Paraffin-Embedded Tissues by Immunohistochemistry

Abstract

Background: We evaluated CD30 and CD56 expression in lymphoblastic lymphoma (LBL) and correlated the results with clinicopathological features and prognosis. Methods: Immunohistochemical (IHC) staining was performed on 85 formalin-fixed paraffin-embedded LBL specimens using two CD30 clones and one CD56 antibody clone. Results: Weak and diffuse expression of CD30 was expressed in 4.7% (clone Ber-H2) or 14.1% (clone EPR4102) in LBL, while CD56 was expressed in 24.7%. CD30 and CD56 expression correlated with lactate dehydrogenase levels. CD56-positive expression was closely associated with an unfavorable prognosis. Although CD30 expression exhibited a trend toward poorer overall survival, it did not reach statistical significance. Conclusion: CD56 is a potential negative prognostic marker. These findings suggest that CD30 and CD56 targeted therapies could be potential therapeutic targets for LBL patients.

Keywords:

• lymphoblastic lymphoma
• CD30
• CD56
• immunohistochemistry
• FFPE tissues

Ethics approval

Since this study is retrospective, the Ethics Committee exempted this study.

Disclosure statement

No potential conflict of interest was reported by the authors.

Data availability statement

Data are available on request to the corresponding author. All data relevant to the study are included in the article. All data that are publicly available and used in the writing of this article in the text.

Additional information

Funding

This study was supported by the National Natural Science Foundation of China (Grant Nos. 81972516), Natural Science Foundation of Guangdong Province (Grant No. 2021A1515012448); President Foundation of Nanfang Hospital, Southern Medical University (Grant No. 2018B012).